Zacks Investment Research lowered shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from a buy rating to a hold rating in a research report sent to investors on Friday.
According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “
A number of other research firms also recently commented on ADMS. Cowen set a $55.00 price objective on Adamas Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, December 13th. Northland Securities assumed coverage on Adamas Pharmaceuticals in a research note on Wednesday, November 29th. They issued an outperform rating on the stock. BidaskClub downgraded Adamas Pharmaceuticals from a buy rating to a hold rating in a research note on Thursday, December 14th. Piper Jaffray Companies set a $52.00 price objective on Adamas Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, December 19th. Finally, Noble Financial boosted their price objective on Adamas Pharmaceuticals from $33.00 to $48.00 and gave the stock a buy rating in a research note on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. Adamas Pharmaceuticals has an average rating of Buy and an average price target of $44.86.
Shares of Adamas Pharmaceuticals (ADMS) opened at $32.15 on Friday. Adamas Pharmaceuticals has a 12 month low of $13.50 and a 12 month high of $38.22. The company has a quick ratio of 8.32, a current ratio of 8.35 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $732.34, a price-to-earnings ratio of -9.57 and a beta of 1.13.
Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.01) by ($0.03). During the same period in the prior year, the company earned ($0.66) earnings per share. The business’s quarterly revenue was down 99.3% compared to the same quarter last year. research analysts forecast that Adamas Pharmaceuticals will post -3.84 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC acquired a new position in shares of Adamas Pharmaceuticals in the 2nd quarter worth $109,000. SG Americas Securities LLC acquired a new position in shares of Adamas Pharmaceuticals in the 3rd quarter worth $110,000. Quantbot Technologies LP acquired a new position in shares of Adamas Pharmaceuticals in the 3rd quarter worth $119,000. Virtu KCG Holdings LLC purchased a new position in shares of Adamas Pharmaceuticals during the second quarter valued at $184,000. Finally, Sei Investments Co. grew its holdings in shares of Adamas Pharmaceuticals by 1,105.0% during the third quarter. Sei Investments Co. now owns 8,760 shares of the specialty pharmaceutical company’s stock valued at $185,000 after buying an additional 8,033 shares in the last quarter. Institutional investors and hedge funds own 79.40% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://transcriptdaily.com/2018/01/09/zacks-investment-research-lowers-adamas-pharmaceuticals-adms-to-hold.html.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.